For more information about Debiopharm Group™, please visit: www.debiopharm.com .About Curis, Inc. Curis is an oncology focused company seeking to develop, targeted drug candidates for the treatment of human cancers. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Debio 0932, an oral HSP90 inhibitor is being developed by Curis' collaborator, Debiopharm, for multiple oncology indications. Curis is leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com. Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Debio 0932's potential benefit to patients with renal cell carcinoma. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates", "assumes", "will", "may," "could" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Debiopharm may not be able to successfully enroll patients in this Phase I study, Debiopharm may experience delays, setbacks and failures in its clinical development of Debio 0932, and Debio 0932 may cause unexpected toxicities. Moreover, positive results in preclinical studies of Debio 0932 may not be predictive of similar results in human clinical trials, and promising results from early clinical trials of Debio 0932 may not be replicated in later clinical trials. Debiopharm may not achieve projected research, development and commercialization goals in its expected time frames. Curis also faces other important risks relating to, among other things, the successful development and commercialization of its and its collaborators' product candidates and its business, operations, financial condition and future prospects generally, that are discussed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and other filings that it periodically makes with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof. Curis disclaims obligation to update any forward-looking statements except to the extent required by law.
CONTACT: Debiopharm International SA Contact Beatrice Hirt Communication Coordinator Tel.: +41 (0)21 321 01 11 firstname.lastname@example.org Additional Media Contacts In London Maitland Brian Hudspith Tel: +44 (0)20 7379 5151 email@example.com In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel: +1 212-845-4292 Fax: +1 212-845-4260 firstname.lastname@example.org Curis, Inc. Contacts Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Tel.: +1 617 503 6605 email@example.com Michael P. Gray Chief Financial and Chief Operating Officer Tel.: +1 617 503 6632 Fax: +1 617-503 6500 firstname.lastname@example.org